Pak Fah Yeow International Limited (HK:0239)
:0239
Top Page
Pak Fah Yeow International Limited
(0239)
Select Model
Select Model
Rating:67Neutral
Price Target:
HK$2.50
▲(5.04% Upside)
Action:ReiteratedDate:10/28/25
Pak Fah Yeow International Limited receives an overall stock score of 67, driven primarily by its mixed financial performance (score: 68, weight: 50%), with a strong balance sheet offset by declining revenue and cash flow concerns. Valuation is a positive factor (score: 75, weight: 20%) due to a low P/E ratio and high dividend yield, while technical analysis (score: 60, weight: 30%) indicates a neutral outlook with mild bullish trends. The score reflects financial stability tempered by growth challenges.
Positive Factors
Strong Profitability Margins
High profitability margins indicate efficient operations and strong pricing power, which can support long-term financial stability and growth.
Negative Factors
Declining Revenue
Declining revenue growth suggests challenges in market demand or competitive positioning, which could impact long-term business sustainability if not addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability Margins
High profitability margins indicate efficient operations and strong pricing power, which can support long-term financial stability and growth.
Read all positive factors
Pak Fah Yeow International Limited (0239) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$747.94M
Dividend Yield7.52%
Average Volume (3M)22.62K
Price to Earnings (P/E)4.9
Beta (1Y)-0.09
Revenue Growth-24.96%
EPS Growth-26.43%
CountryHK
Employees106
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.17
Shares Outstanding311,640,000
10 Day Avg. Volume26,750
30 Day Avg. Volume22,616
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)1.06
Price to Sales (P/S)3.26
P/FCF Ratio9.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pak Fah Yeow International Limited Business Overview & Revenue Model
Company Description
Pak Fah Yeow International Limited, together with its subsidiaries, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the Uni...
How the Company Makes Money
Pak Fah Yeow International Limited generates revenue primarily through the sale of its medicinal products, with key revenue streams coming from both domestic and international markets. The company markets its flagship medicated oil and other topic...
Pak Fah Yeow International Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
85
Very Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 199.54M | 236.91M | 259.31M | 147.20M | 139.82M | 109.34M |
| Gross Profit | 173.45M | 203.20M | 167.59M | 74.06M | 68.71M | 41.48M |
| EBITDA | 105.12M | 105.73M | 136.81M | 45.90M | 54.67M | -25.22M |
| Net Income | 70.97M | 78.63M | 105.04M | 29.95M | 38.19M | -38.36M |
Balance Sheet | ||||||
| Total Assets | 852.25M | 843.35M | 907.47M | 823.14M | 837.75M | 795.40M |
| Cash, Cash Equivalents and Short-Term Investments | 365.20M | 290.02M | 277.61M | 180.34M | 178.28M | 131.48M |
| Total Debt | 4.79M | 4.20M | 4.74M | 5.50M | 16.21M | 17.86M |
| Total Liabilities | 148.07M | 111.45M | 142.28M | 115.91M | 130.03M | 122.20M |
| Stockholders Equity | 704.18M | 731.91M | 765.18M | 707.23M | 707.72M | 673.19M |
Cash Flow | ||||||
| Free Cash Flow | 57.39M | 78.02M | 144.84M | 39.76M | 69.54M | 7.62M |
| Operating Cash Flow | 57.94M | 78.96M | 147.90M | 39.92M | 70.36M | 8.26M |
| Investing Cash Flow | 2.37M | -3.19M | 16.65M | -6.67M | -565.00K | -637.00K |
| Financing Cash Flow | -66.91M | -67.54M | -48.96M | -33.91M | -22.41M | -29.07M |
Pak Fah Yeow International Limited Technical Analysis
Positive
2.38
Price Trends
2.38
Positive
2.40
Negative
2.39
Positive
Market Momentum
<0.01
Negative
55.16
Neutral
96.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0239, the sentiment is Positive. The current price of 2.38 is above the 20-day moving average (MA) of 2.36, above the 50-day MA of 2.38, and below the 200-day MA of 2.39, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.16 is Neutral, neither overbought nor oversold. The STOCH value of 96.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0239.
Pak Fah Yeow International Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.31B | 5.18 | 10.88% | ― | 10.26% | 6.24% | |
68 Neutral | HK$677.60M | 24.59 | 1.57% | 9.43% | -1.99% | -81.52% | |
67 Neutral | HK$747.94M | 4.94 | 9.88% | 7.52% | -24.96% | -26.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$926.38M | -2.84 | -48.86% | ― | -43.46% | -96.48% | |
46 Neutral | HK$416.29M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% | |
42 Neutral | HK$163.16M | -4.22 | -30.35% | ― | -17.32% | 55.74% |
* Healthcare Sector Average
HK:0239
Pak Fah Yeow International Limited
2.40
0.42
21.21%
HK:8049
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
2.33
0.96
70.20%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.37
0.01
2.78%
HK:1498
PuraPharm Corp. Ltd.
0.31
-0.20
-39.00%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.26
1.02
425.00%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.80
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.